Consumers are looking backward to move forward in their nutrition. In an era flooded with health claims, ultra-processed foods, and ingredient lists longer than a novel, a growing number of shoppers and diners are gravitating toward something that feels both familiar and honest: the healthy foods their grandparents and other ancestors grew up eating.

The World Health Organization defines a healthy diet as one rich in vegetables, legumes, whole grains, and fruits. This description maps almost perfectly onto traditional cuisines that have sustained populations for centuries.

For food processors, foodservice operators, food manufacturers, and retailers, this shift is an invitation to develop more nutritious portfolios and minimally processed foods that connect with where consumers already are. It’s also central to Griffith Foods’ 2030 aspiration: developing a nutritious and sustainable portfolio.

58% of consumers are paying closer attention to ingredient lists. Source: FMCG Gurus, June 2025.

Why Consumers Are Turning to Traditional Foods

The numbers tell a clear story about where consumer priorities have shifted.

Consumers Are Paying Closer Attention to Ingredients and Claims

Around 58% of consumers1 are now paying closer attention to ingredient lists than they were just a year ago. They’re scanning for things they recognize, questioning what they don’t, and growing more skeptical of health halos built on marketing rather than substance.

Jackie Schulz, Sr. Director of Global Nutrition at Griffith Foods, is direct about what earns longterm trust:

Claims that have evidence to support their efficacy are those that carry the most weight. Including meaningful amounts of ingredients with scientific evidence that they can have an impact on health, through demonstrated mechanisms, will help build trust much more than including ingredients that imply health without it.

Consumers Are More Interested in Vegetable-Based Entrées

FMCG Gurus data shows that 55% of consumers1 actively want to maximize their intake of “good” ingredients. Meanwhile, about 54% of global consumers2 want a wider variety of vegetable-based entrées on menus.

This echoes what we see in traditional diets around the world—many of the world’s longestlived, healthiest populations, like those eating along the Mediterranean, in parts of Latin America, and across Asia, have frequently centered on vegetables and plant-based foods.

Emily Schlag, Corporate Executive Chef at Griffith Foods, points to social media as an accelerant for this trend:

“We see an increased desire to learn about other cultural foods, especially those from countries that are known to have healthy populations.”

How Traditional Foods Deliver Nutrient Density

Nutritional performance is a primary appeal of traditional foods. At Griffith Foods, nutrient density is defined rigorously, using the Nutrient-Rich Foods Index. This framework measures the quantity of beneficial nutrients relative to those we should limit, like sodium, saturated fat, and sugar.

Chain Yin, Regional Nutritionist at Griffith Foods, adds that this thinking extends beyond individual ingredients:

We carefully craft nutrient-dense foods and solutions at the level of the full eating experience, not just a single ingredient. We look at each component of a product to identify opportunities to reduce nutrients of concern while incorporating ingredients that enhance nutritional value.

Which Nutrient-Dense Foods Have Stood the Test of Time?

Three categories stand out for their nutritional credentials, culinary innovation and versatility.

1. Ancient Grains

Bulgur, sorghum, farro, barley, millet, quinoa, amaranth, and fonio have been foundational to diets across the Middle East, West Africa, and beyond for thousands of years. Today they’re earning renewed attention as fiber-rich foods that support digestive health, steady energy, and longer-lasting satiety.

Improved processing has also unlocked new applications for these grains. As Chef Emily puts it:

“In years past, major complaints were long cooking times and bitter flavors. With improvements in processing, we can have tender grains with pleasantly nutty and earthy flavors.”

The result? Ancient grains that slot naturally into modern menus—toasted millet as a crispy salad topping, popped sorghum seasoned like popcorn, creamy farro porridge as a morning staple, barley risotto as a weeknight centerpiece.

2. Legumes and Plant-Based Protein

Lentils, adzuki beans, and chickpeas sit at the crossroads of plant-based protein and fiber-rich foods. The American Heart Association champions legumes as a heart-healthy protein source.

A bowl of heavily seasoned chickpeas.

Schulz notes that traditional diets across Latin America, Asia, and Africa tend to be higher in legume and vegetable content. They can be higher in fiber, as well as micronutrients such as potassium, magnesium, and phytonutrients—areas where Western diets tend to fall short.

3. Herbs and Spices

Turmeric and lemon verbena aren’t just garnishes. In traditional cuisines from South Asia to North Africa, herbs and spices have long served as both flavor carriers and functional ingredients.

Chain Yin highlights how this plays out in practice:

“In Chinese and Indian cuisine, herbs, spices, pulses, and whole grains are often paired with time-honoured cooking methods like fermentation and slow boiling, which help create depth of flavor while supporting overall nourishment.”

Nutritious Tradition from Around the World

When considering cultures that can inspire your menu development, four regions stand out.

Mediterranean

The Mediterranean diet remains the most rigorously studied traditional eating pattern in the world, with the strongest evidence for longevity and chronic disease prevention.

This diet is rooted in an abundance of vegetables, legumes, whole grains, olive oil, and herbs, with animal proteins playing a supporting role rather than leading. Fiber, potassium, magnesium, and phytonutrients flow naturally from the pattern as a whole.

China

In Chinese cuisine, nutrient density is built into technique as much as ingredient choice.

Fermentation, slow boiling, and careful spice layering preserve and enhance nutritional value while developing flavor.

Today, health-focused cafés in China are putting ancient grains front and center, such as pairing barley, lentils, and soba noodle bowls with pomegranate-marinated sea bass, demonstrating that the tradition already has a modern expression ready to scale.

West Africa

West African culinary traditions have long relied on legumes, whole grains, and vegetables as dietary staples. Fonio and sorghum, fiber-rich foods with strong micronutrient profiles, have sustained populations across the region for centuries.

Aboboi, a hearty bean and red pepper stew, is a representative example: plant-based protein and fiber at the center of a dish built entirely from whole, recognizable ingredients.

Korea

Korean cuisine offers one of the most compelling models for integrating plant-based protein and fermented foods into everyday eating. Adzuki bean bibimbap places legumes at the heart of a balanced, complete meal, while fermented staples like kimchi contribute beneficial cultures alongside vitamins and fiber.

A Korean bowl of rice, beef bulgogi, carrots, cabbage, bean sprouts, cucumbers, a fried egg, and chili sauce drizzled on top.

Move Forward by Looking to the Past

Consumer appetite is clear, and the food innovation opportunity is now.

Anchoring product development in nutrient-dense and clean-label food ingredients from traditional foods can spark new opportunities.

To discover how these food and nutrition trends are shaping the next wave of product development, explore Griffith Foods’ 2026 Food & Flavor Outlook.

FAQs

Why are food developers turning to traditional foods now?

Consumer trust in heavily processed foods is eroding. With 58% of consumers paying closer attention to ingredient labels, traditional foods offer recognizable ingredients, proven nutritional profiles, and an authenticity that health claims alone can’t replicate.

What makes ancient grains, legumes, and herbs so relevant to modern menus?

These ingredients sit at the intersection of nutrient density and culinary versatility. Improvements in processing have made ancient grains easier to cook and more palatable. Ancient grains, legumes, and herbs also bring plant-based protein, fiber, and functional benefits that align with where consumer demand is heading.

Which traditional food cultures offer the most menu development inspiration?

The Mediterranean, China, West Africa, and Korea each offer well-documented, nutrientdense eating patterns that translate naturally into modern formats—from barley risotto and adzuki bean bibimbap to fonio-based dishes and fermented staples like kimchi.

View original content here.

About Griffith Foods

Griffith Foods is a global product development partner helping food companies meet the evolving needs of consumers with high-quality, culinary driven, customized products. Founded in 1919 and headquartered in Alsip, Illinois, USA, Griffith Foods is a family-owned business known for collaborative innovation guided by its purpose to “Blend Care and Creativity to Nourish the World.” Operating in over 40 countries across six continents, Griffith Foods employs more than 5,000 people, including over 40 chefs and 340 food scientists, who work together to create solutions that nourish people, planet, and communities. The company’s product capabilities include seasonings, sauces, dressings, coating systems, and alternative protein solutions. Griffith Foods’ primary areas of focus include Foodservice, Food Manufacturers, Protein Processors, and Retail.

1 FMCG Gurus June 2025.

2 Technomic, “Global Consumer Trends: Q2 2025 biannual update of shifting consumer usage and attitudes,” 2025.

 

SAN FRANCISCO–(BUSINESS WIRE)–  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Farallon Capital Management, L.L.C. (on behalf of funds managed jointly with Farallon Capital Europe LLP and Farallon Partners, L.L.C.) (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming

VANCOUVER, Wash.–(BUSINESS WIRE)–ZoomInfo (NASDAQ: GTM), the all-in-one AI GTM platform, has confirmed that ZoomInfo MCP is now live as a connector inside Replit’s Integrations marketplace. The connector gives users building on Replit natural-language access to verified company and contact data through GTM.AI, ZoomInfo’s headless GTM context layer, with no custom API integration required. A user connects the ZoomInfo MCP connector once, from inside Replit’s Settings panel. From that point, an

CHICAGO–(BUSINESS WIRE)–SullivanCotter, the nation’s leading independent consulting firm in the assessment and development of total rewards programs, workforce solutions, and data products for health care and not-for-profit organizations, has released results from its 2026 Health Care Management and Executive Compensation Survey. Now in its 34th year, this industry-leading benchmarking resource includes compensation data on positions across more than 3,600 health care organizations, including

QINGDAO, China, Sept. 24, 2026 (GLOBE NEWSWIRE) — Maase Inc. (NASDAQ: MAAS) (“MAAS” or the “Company”), an artificial intelligence (“AI”)-centric full-scene digital systems provider and operator, today announced that its subsidiary, Huazhi Future (Chongqing) Technology Co., Ltd. (“Huazhi Future”), entered into a tripartite cooperation framework agreement (the “Agreement”) recently in Singapore with Chungking New Gardner Enterprise Management Consulting Co., Ltd. (“New Gardner”) and SAGELIGHT VENTURES PTE. LTD. (“Sagelight Ventures”).

Under the Agreement, the three parties intend to use Singapore as a strategic hub for overseas business development and compliant operations and jointly advance the development and commercialization of a global AI computing, model services and applications platform. Huazhi Future will be responsible for platform development and the integration of global computing resources, AI model and application interfaces, providing overseas customers with computing services, AI model access and industry-specific AI applications. In parallel, the parties plan to advance the deployment of large-scale computing centers and edge containerized computing infrastructure based on overseas market demand and, subject to applicable local regulatory requirements, explore innovative and compliant commercial models related to computing infrastructure. In addition, the parties plan to develop industry-specific AI systems and applications for government agencies, industry associations, enterprises, universities and research institutions in Southeast Asia, further integrating computing resources, model services and industry-specific applications.

Strategic Significance

The cooperation is expected to further connect Huazhi Future’s existing capabilities in distributed intelligent computing infrastructure, model aggregation services and enterprise AI applications, while extending these capabilities into overseas markets.

In computing infrastructure, Huazhi Future is advancing the deployment of its Star Distributed Intelligent Computing Center project, with related business activities already underway in Chongqing and Xinjiang, while continuing to explore opportunities in overseas markets including Singapore, Malaysia and Kazakhstan. In model services, the Company has launched a multimodal AI model aggregation service platform in China, providing access to more than 100 leading AI models and related model services, and has accumulated experience in model integration, AI model usage metering, platform operations and enterprise services.

Building on these capabilities, Huazhi Future plans to integrate computing resources, AI model access and usage services and industry-specific AI applications into a unified overseas service platform. Through Singapore, the Company expects to connect with Southeast Asia and other international markets, thereby expanding its enterprise AI services globally.

Management Commentary

Min Zhou, Chief Executive Officer of MAAS, commented: “This tripartite cooperation represents an important step in further advancing the global expansion of our AI infrastructure and enterprise AI services. Singapore offers a mature international business environment, a well-developed industrial ecosystem and a strategic location connecting Southeast Asia and other global markets. Through this cooperation, we aim to extend Huazhi Future’s capabilities in computing resource integration, AI model access and usage services and industry-specific AI applications into additional international markets, while gradually building a global service ecosystem spanning underlying computing infrastructure, AI model services and industry-specific applications.”

Dr. Zhifeng Li, Chief Technology Officer of MAAS, commented: “Our objective is to reduce the complexity enterprises face in accessing global computing resources and AI model capabilities. The platform is expected to connect different types of computing resources, AI model interfaces and industry-specific applications through a unified framework for access, metering, scheduling and operations, providing overseas customers with more standardized and scalable AI services. As enterprise adoption of AI evolves from reliance on individual model access toward multi-model environments, AI agents and industry-specific applications, we believe unified access to computing and model services will become an increasingly important part of enterprise AI infrastructure.”

About MAAS

Maase Inc. (NASDAQ: MAAS) is an integrated provider and operator of an artificial intelligence (“AI”)-centric full-scene digital systems. Our businesses focus on areas of flexible energy deployment and intelligent commercial network operation, and provide closed-loop solutions from computing infrastructure, smart hardware and full-scene services, aiming to achieve large-scale implementation of AI technologies across industries. Powered by our dual engines of intelligent technology and ecosystem integration, through strategic industry consolidation and continuous improvement in operations, our mission is to build up an open and collaborative industrial ecosystem and provide our customers with efficient, reliable and sustainable intelligent products and solutions. We will continuously explore and consolidate high-quality technological and commercial resources globally and explore industrial application scenarios of AI technologies. For more information, please visit: https://ir.maaseai.com/.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar statements. Among other things, statements regarding the Company’s strategies, business plans, future business development and prospects are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including, but not limited to, whether the Agreement will be performed, renewed, or generate the anticipated benefits; the Company’s goals and strategies; its future business development; the demand for and acceptance of its products and services; technological changes; the economic environment; its reputation and brand; the effects of competition and pricing; governmental regulation; and general economic and business conditions in the domestic and international markets in which the Company operates, as well as assumptions underlying or related to any of the foregoing risks and other risks disclosed in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”). Investors should not place undue reliance on these forward-looking statements. All information provided in this press release is as of the date of this press release, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law. Further information regarding these and other risks is included in the Company’s filings with the SEC, which are available for review at www.sec.gov.

CONTACT: Investor Relations Contact

For more information, please contact:

Investor Relations

Phone: +86-532-66030885

Email: ir@maaseai.com

Website: https://ir.maaseai.com/

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

OTTAWA, Ontario, Sept. 24, 2026 (GLOBE NEWSWIRE) — (TSX: MNT/MNT.U) The Royal Canadian Mint (the “Mint”) announced today that it has completed its previously-announced follow-on offering of 501,175 exchange-traded receipts (“ETRs”) under the Mint’s Canadian Gold Reserves program at a price of C$65.82 per ETR for gross proceeds of C$32,987,338.50 (the “Offering”). The newly-issued ETRs have been listed on the Toronto Stock Exchange and are fully fungible with all other outstanding ETRs. The Offering was made on a prospectus-exempt basis pursuant to the terms of exemptive relief orders issued in favour of the Mint by the Ontario Securities Commission.

Each ETR provides its holder with direct legal and beneficial ownership in physical gold bullion held in the custody of the Mint at its facilities in Ottawa, Ontario. The newly-issued ETRs have a per ETR entitlement to gold that is the same as all other outstanding ETRs, which as of today’s date is 0.0103490 of one fine troy ounce.

Subject to certain restrictions, ETR holders are entitled to redeem their ETRs for physical gold bullion with a minimum purity of 99.99% or for cash.

The Offering was made by a syndicate of underwriters co-led by TD Securities Inc. and National Bank Financial Inc. and included CIBC World Markets Inc., RBC Dominion Securities Inc., BMO Nesbitt Burns Inc., Scotia Capital Inc., Canaccord Genuity Corp., iA Private Wealth Inc., Raymond James Ltd., ATB Capital Markets Corp., Desjardins Securities Inc., Manulife Wealth Inc. and Hampton Securities Limited.

The ETRs have not been and will not be registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any offer, solicitation or sale of the ETRs in any jurisdiction in which such an offer, solicitation or sale would be unlawful.

Additional information on the Canadian Gold Reserves program and the ETRs is available on the Canadian Gold Reserves’ website at www.reserves.mint.ca and on the Mint’s issuer profile on SEDAR+ at www.sedarplus.ca.

About the Royal Canadian Mint

The Royal Canadian Mint is the Crown corporation responsible for the minting and distribution of Canada’s circulation coins. The Mint is one of the largest and most versatile mints in the world, producing award-winning collector coins, market-leading bullion products, as well as Canada’s prestigious military and civilian honours. As an established London Good Delivery and COMEX-approved refiner, the Mint also offers a full spectrum of best-in-class gold and silver refining services. The Mint has issued exchange-traded receipts under its Canadian Gold Reserves (TSX: MNT/MNT.U) and Canadian Silver Reserves (TSX: MNS/MNS.U) programs, which provide holders with direct legal and beneficial ownership in physical bullion held in the custody of the Mint at its facilities. For more information on the Mint, its products and services, visit www.mint.ca.

For more information, please contact:

Media Inquiries Investor Relations
Alex Reeves
Senior Manager, Public Affairs
Royal Canadian Mint
613-884-6370
reeves@mint.ca
Frank Caterina
Program Associate, ETR Investor Relations
Royal Canadian Mint
1-866-677-1477
reserves@mint.ca

Termination of Financing is Expected to Avoid Dilution of More Than 8 Million Shares

Fort Lauderdale, FL, Sept. 24, 2026 (GLOBE NEWSWIRE) — Algorhythm Holdings, Inc. (the “Company”) (NASDAQ: RIME) – a diversified holding company that owns and operates Azure Energy, a renewable power plant developer, and SemiCab, a leading AI enabled logistics provider, today announced the voluntary termination of a previously disclosed settlement transaction completed under Section 3(a)(10) of the Securities Act with Continuation Capital, Inc. The Company would have been required to issue more than 8 million additional shares of common stock to pay off the remaining balance of approximately $1.4 million.

“One of our highest priorities in the near term is to proactively strengthen our balance sheet, eliminate existing dilutive financings, and lower our cost of capital,” commented Andrew Thompson, CEO of Algorhythm Holdings. “In furtherance of this, we recently announced the retirement of all of our outstanding shares of Series A Preferred Stock. Terminating this $1.4 million financing was the next step in this process.”

“We made a conscientious decision to partner with Algorhythm and leverage our value contribution for the benefit of all Algorhythm shareholders. We have compelling business opportunities in place and in the pipeline. We believe it is paramount to dramatically improve the financing solutions available to the Company in order to execute upon our long-term business plan,” concluded Mr. Thompson.

The Company recently acquired Azure Energy in an all-stock transaction valued at $23 million, acquiring contracts expected to generate revenue of more than $10 million through the end of 2027. The Company intends to use this revenue to lower its cost of capital, strengthen its balance sheet, and fund its future growth.

About Algorhythm Holdings

Algorhythm Holdings, Inc. is a diversified holding Company that owns and operates two businesses — Azure Energy and SemiCab.

Azure Energy is a leading developer of renewable biomass power generation infrastructure. Its team consists of some of the most experienced biomass power plant experts in the U.S. today. Collectively this team has designed and built 72 facilities generating 17.5GW of renewable power to date. The company was launched in 2025 and has already secured equity participation rights valued at over $220 million in net present value through multiple power plants projects that are currently under construction. The Company has multi-year contracts in place that will yield significant fee-income consulting revenues, and is currently generating scaling, positive EBITDA. For additional information, please go to: http://www.azure-energy.co.

SemiCab is an AI-enabled logistics software provider. Since 2020, SemiCab has enabled major retailers, brands and transportation providers to address common supply-chain problems globally. Its AI-enabled, cloud-based Collaborative Transportation Platform achieves the scalability required to predict and optimize millions of loads and hundreds of thousands of trucks. SemiCab uses real-time data from API-based load tendering and pre-built integrations with TMS and ELD partners to orchestrate collaboration across manufacturers, retailers, distributors, and their carriers. SemiCab uses AI/ML predictions and advanced predictive optimization models to enable fully loaded round trips. With SemiCab’s AI platform, shippers pay less and carriers make more without having to change a thing. For additional information, please go to: http://www.semicab.com.

Investor Relations Contact
Brendan Hopkins
407-645-5295
investors@algoholdings.com
www.algoholdings.com

Media Contact
FischTank PR
Algorhythm@fischtankpr.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as “expects,” “anticipates,” “believes,” “will,” “will likely result,” “will continue,” “plans to,” “potential,” “promising,” and similar expressions. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described from time to time in the Company’s reports filed with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. You should not place undue reliance on any forward-looking statement, each of which applies only as of the date of this press release. Except as required by law, we undertake no obligation to update or revise publicly any of the forward-looking statements after the date of this press release to conform our statements to actual results or changed expectations, or as a result of new information, future events or otherwise.

Employers can now fully fund, subsidize, or discount the world’s leading smart ring for their workforce through Workday Benefits & Wellness

SAN FRANCISCO, Sept. 24, 2026 (GLOBE NEWSWIRE) — ŌURA, a leading health intelligence platform and maker of the world’s smallest smart ring, today announced it has joined Workday Wellness, an AI-powered platform that gives employers a real-time view into which benefits their employees actually use and want, and helps them build a better benefits program around that.

Through the partnership, Oura will appear as a benefit option inside Workday Wellness, and for the first time, employers will be able to share the cost of Oura Ring with employees rather than covering it entirely on their own, whether by fully funding it, subsidizing part of the cost, offering a discount, or making it available for employees to purchase on their own with the option to administer payroll deductions through Workday.

“Employers want to invest in benefits their people will actually use, not just enroll in,” said Dor Kilroy, Chief Commercial Officer at Oura. “Workday Wellness gets us in front of more employers who care about that, and helps more people build the daily habits, better sleep, lower stress, that add up to real, lasting health.”

Making Oura Ring a Viable Employer Benefit
HR and benefits leaders are under pressure to address burnout, presenteeism, and declining productivity, and are looking for benefits their people will actually use. Oura offers a simple, science-backed way to care for your health, and this partnership makes it easier for employers to give their teams access to it.

Oura Ring continually watches for shifts in nighttime breathing, blood pressure, and respiratory patterns, flagging changes early so employees stay ahead of their health, and supports whole-person health across six pillars: sleep, stress, heart, metabolic, women’s health, and activity. Here’s how employers can bring it to their teams.

Workday Wellness Program Details
The integration gives employers several ways to structure the core or voluntary benefit for their organization:

  • Fully fund Oura Ring for their entire workforce, covering the full cost so employees pay nothing out of pocket.
  • Subsidize part of the cost, contributing a set amount or percentage per Oura Ring and sharing the investment with the employee.
  • Offer a discount on Oura Ring standard price, without the employer taking on the full cost of the program.
  • Make the benefit available on a voluntary basis, giving employers the option to use wellbeing dollars to help fund it and employees the option to pay their portion interest-free over time through payroll deduction in Workday.

Built for Benefits People Use
Workday Wellness is built to help employers maximize the benefits their people actually use, not just enroll in. More than 1,200 organizations already offer Oura Ring today. Among Oura’s paying members, 80% renew after one year, and 80% open the Oura App five or more days a week. Paying members also report meaningful wellness improvements: in month one, they self-report a 90% improvement in overall health, 81% improvement in stress management, and 79% improvement in productivity.

Built Around Employee Privacy
Employee Oura data stays completely separate from the benefits program, with no visibility for employers or Workday’s AI-powered benefits models into any individual’s sleep, Readiness, stress, or other health metrics. Every employee remains in control of their own personal data and can choose when and whether to share it with their employer.

Oura Ring 5 will be available to eligible employers through Workday Wellness beginning later this year. Availability is limited to Workday HCM customers who adopt Workday Wellness.

About ŌURA
ŌURA is a health intelligence platform designed to transform how people understand and manage their health in everyday life. Oura’s platform is anchored by Oura Ring, the world’s leading smart ring that empowers you to live healthier, longer. Oura supports millions of members worldwide across sleep, activity, stress, readiness, women’s health, metabolic health, and heart health. Oura Ring is purpose-built to leverage the finger’s unique physiological advantages for photoplethysmography (PPG) measurement, producing a stronger signal than wrist-based wearables. The core metrics of the lightweight Oura Ring are scientifically validated against gold standards and the ring tracks 50+ health metrics continuously, empowering both individuals and thousands of research teams, healthcare providers, sports teams, and organizations. Trusted by an ecosystem of more than 1,200 partners, Oura is advancing the future of preventative health with privacy and security at the forefront.

Founded in Finland in 2013, Oura is headquartered in San Francisco with E.U. headquarters in Oulu, Finland.

Oura Ring is not a medical device and is not intended to diagnose, treat, cure, monitor, or prevent medical conditions or illnesses.

Contacts
press@ouraring.com

Plan combines up to $25 million in new capital with restructuring of $3 million in existing debt to support commercial execution and manufacturing expansion

Company anticipates positive monthly operating cash flow by the end of Q1 2027

Philip A. Barach to join the Board, bringing financial expertise and a focus on capital discipline

FLORHAM PARK, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced an initial closing generating over $10 million in gross cash proceeds from a private placement of senior secured convertible notes and warrants. The closing is part of a broader recapitalization plan contemplating up to $25 million in new cash investment, including the initial closing, and the restructuring of approximately $3 million in existing indebtedness.

The financing follows significant operating improvements, including a reduction in monthly cash burn of more than $1 million, personnel optimization and a sharper allocation of resources toward revenue-generating opportunities. With a lower operating cost base, purpose-built manufacturing infrastructure and existing cenplacel-L inventory that management estimates represents approximately $40 million in potential sales value, Celularity is focused on converting its scientific and manufacturing assets into revenue and sustained growth.

The Company also announced the appointment of Philip A. Barach to its Board of Directors, bringing financial expertise and an emphasis on capital allocation, operating accountability and stockholder returns.

“We have built substantial scientific and manufacturing capabilities, and we are taking decisive action to translate those investments into commercial results,” said Robert J. Hariri, M.D., Ph.D., Chairman and Chief Executive Officer. “Our lower cost structure, existing cellular product inventory and purpose-built manufacturing facility provide a powerful foundation for growth. This financing supports our ambition to expand revenue-producing relationships, increase utilization of our manufacturing capabilities and pursue opportunities across cellular and regenerative medicine and complementary longevity therapeutics. Our objective is to build a business that can help advance human healthspan while delivering lasting value to stockholders.”

“Extending healthy human life is an extraordinary opportunity, and Celularity has spent years building capabilities to help address it,” added Peter H. Diamandis, M.D., Co-Founder and Director of Celularity. “The next phase is about translating that foundation into scale by connecting our science with market access, expanding productive partnerships and making our infrastructure an engine of growth. I’m pleased to welcome Philip to the Board and look forward to James joining us as we work to realize that potential.”

A Lower Cost Base and a Sharper Focus on Returns

Celularity has implemented substantial budgetary improvements, reduced monthly cash burn by more than $1 million and optimized personnel and spending around its strategic priorities. These actions are designed to make invested capital go further and strengthen the Company’s ability to translate additional revenue into improved operating performance.

Building on these operating improvements and anticipated revenue growth, Celularity expects to achieve positive monthly operating cash flow by the end of the first quarter of 2027. This outlook reflects management’s expectations for increased manufacturing revenue, deployment of existing cellular product inventory and continued control of operating expenses.

“Since my initial investment, Celularity has demonstrated the willingness to make difficult operating decisions and reduce its monthly cash burn, enabling the Company to concentrate resources on bolstering revenue generation,” said Philip A. Barach. “That progress was a catalyst for my additional investment and my agreement to join the Board. I see an opportunity to pair a leaner operating structure with substantial scientific and manufacturing assets to build a stronger, more valuable company. My focus will be on directing capital toward the most compelling opportunities and holding the business accountable for measurable results.”

Expanding Manufacturing Relationships

The Company’s growth strategy centers on turning its existing scientific and manufacturing assets into revenue-producing partnerships. Its collaboration with MuseCell Innovations Pte. Ltd. (“MCI”) illustrates that strategy, establishing U.S. manufacturing capabilities for the Dezawa MuseCell® platform and related products at Celularity’s Florham Park facility. The relationship provides an opportunity to increase facility utilization, generate manufacturing revenue and build a foundation for broader commercial expansion. Celularity intends to pursue additional relationships that similarly put its existing infrastructure and expertise to productive use while maintaining a disciplined approach to capital investment.

Approximately $40 Million in Potential Sales From Existing cenplacel-L Inventory

Celularity currently holds inventory of cenplacel-L, its investigational placenta-derived allogeneic cell therapy, that management estimates represents approximately $40 million in potential sales value. The Company intends to pursue deployment through commercial relationships in permissive jurisdictions where supply and use are legally authorized, subject to applicable local regulatory requirements.

This existing inventory provides a tangible foundation for the Company’s domestic and international growth strategy. Celularity aims to convert that inventory into revenue while expanding relationships that can support recurring demand and broader utilization of its manufacturing capabilities.

Transaction Summary

The transaction combines a private placement of senior secured convertible notes and accompanying warrants with the restructuring of existing indebtedness. The initial closing generated over $10 million in gross cash proceeds, before transaction expenses and repayment of existing indebtedness.

The notes mature 24 months after their respective issuance dates and bear interest at 10% per annum, compounded annually. Notes issued at the initial closing are initially convertible into Class A common stock at $1.50 per share. Accompanying five-year warrants are initially exercisable at $1.50 per share and provide eleven warrant shares for every twenty shares initially issuable upon conversion of the notes.

Conversion and exercise prices are subject to adjustment, and issuances remain subject to applicable ownership limitations and Nasdaq stockholder approval requirements. Additional closings are subject to the applicable investor election procedures and other conditions specified in the definitive agreements. The full recapitalization amount includes potential future funding that has not yet been received, and there can be no assurance that additional closings will occur.

In connection with the transaction, Philip A. Barach is to join Robert J. Hariri and Peter H. Diamandis on a newly constituted five-member Board of Directors, with two additional directors to be announced at a later date. The appointments remain subject to applicable requirements, including completion of the Rule 14f-1 information statement process.

Odeon Capital Group LLC acted as placement agent in connection with the initial closing of the private placement.

Further details regarding the financing, restructured indebtedness, Board arrangements and related agreements will be included in a Current Report on Form 8-K.

The securities have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption. This release does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale in a jurisdiction where such offer, solicitation or sale would be unlawful.

About Celularity

Celularity Inc. (Nasdaq: CELU) is a longevity-focused regenerative and cellular medicine company developing and manufacturing allogeneic and autologous cell therapies derived from the postpartum placenta. Celularity draws on the placenta’s unique biology, immunologic properties and scalable availability to develop therapeutic solutions targeting fundamental mechanisms of aging and age-related disease. Celularity’s cellular therapy portfolio includes cenplacel-L, its placenta-derived allogeneic cell therapy, and other investigational cellular therapies. Celularity is headquartered in Florham Park, New Jersey, where it operates a purpose-built facility supporting the development and manufacture of cellular therapies, advanced biomaterials, and other longevity and wellness-focused products.

For more information, please visit www.celularity.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements regarding potential additional financing closings and the total recapitalization amount; anticipated benefits of the financing and debt restructuring; intended use of proceeds; the anticipated appointment Board members; the sustainability and expected benefits of operating improvements and reduced cash burn; commercial execution, revenue generation and growth, including the anticipated achievement of positive monthly operating cash flow by the end of the first quarter of 2027; the estimated potential sales value, deployment and monetization of existing cenplacel-L inventory; international market access and demand; the anticipated benefits and potential expansion of the MCI collaboration and other commercial relationships; cellular, regenerative and complementary longevity-related therapeutic opportunities; and manufacturing services, utilization, capabilities and expansion. These statements are based on current expectations and assumptions and are not guarantees of future performance.

Actual results could differ materially due to risks and uncertainties, including the Company’s ability to obtain additional funding, satisfy its obligations and continue operations; the secured nature of its indebtedness and consequences of defaults; dilution from conversion of notes and exercise of warrants; satisfaction of conditions to additional closings and the anticipated Board appointment; obtaining stockholder approvals and meeting registration obligations; completing delinquent SEC filings and regaining or maintaining compliance with Nasdaq listing requirements; sustaining cost reductions while maintaining necessary personnel and capabilities; achieving anticipated revenue growth and cash collections within expected timeframes; securing and maintaining authorizations for the supply and use of investigational products; realizing assumed pricing and demand for existing inventory before expiration or obsolescence; clinical, regulatory, manufacturing and intellectual property risks; and the ability of the Company and its collaborators to perform their obligations and develop commercially viable opportunities.

Additional risks are described under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this release, and readers should not place undue reliance on them. Except as required by law, Celularity undertakes no obligation to update or revise these statements.

Investor and Media Contact
info@celularity.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.